

The invention relates to the obtaining genetically-engineered antibodies from the P3 (AcM P3) murine monoclonal antibody, which is produced by the hybridoma deposited under number ECACC 94113026 in accordance with the Budapest treaty, with the purpose of obtaining antibodies which have the same recognition properties as the original but which is less immunogenic. The chimeric antibody contain the variable domains of murine immunoglobulin and the constant regions of human immunoglobulin. The humanized antibody, in addition to containing the constant regions of human immunoglobulin, is modified in the murine frameworks (FRs) region and, in particular, in those areas that can be converted into a T-cell antigenic site, as a result of which some FRS positions are human. Said antibodies can be used for the diagnosis and therapy of different types of tumors.